Analyst Research

Report Title Price
Provider: S&P Capital IQ Factual Report
$150.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cubist Pharmaceuticals Inc Completes Acquisition of Trius Therapeutics Inc


Wednesday, 11 Sep 2013 04:30pm EDT 

Cubist Pharmaceuticals Inc announced that it has completed the previously announced acquisition of Trius Therapeutics Inc for an aggregate upfront cash consideration of approximately $704 million. Effective immediately, Trius common stock will cease to be traded on the NASDAQ. 

Company Quote

62.65
0.07 +0.11%
24 Jul 2014